“Science and Technology Innovation Board Daily”, December 1 (Reporter Wu Xuguang) “The company's nano-imprinting technology is currently being prototyped by several domestic and foreign customers, and is expected to be shipped in batches in the first quarter of next year.” Ge Wenzhi, chairman and general manager of Medicare, said at the third quarter results briefing held today.

Currently, Medicare's nanoimprinting technology is developing non-imaging optical components, mainly used in automotive HUDs, wearable devices, intelligent robots, AR/VR, biomedicine, and various optical sensors.

“The company's nanoimprint technology can be applied to the semiconductor field.” Medicare's board secretary and financial director Hua Zhaohua said in response to questions from investors.

Ge Wenzhi, chairman and general manager of Medicare, said at the performance meeting that the company currently has grayscale nanoimprint lithography technology. Its subsidiary Hangzhou Medicare Microelectronics will enter the factory in June according to the plan, and some nodes have plans to use nanoimprinting instead of lithography processes.

However, an agency source told the “Science and Technology Innovation Board Daily” reporter that at present, the nanoimprinting technology of domestic companies is mainly suitable for the manufacture of micro-nano optical devices such as optical waveguides and wearable devices, and is not suitable for semiconductor chip manufacturing. The nanoimprint technology used by Canon in the lithography field is a different subdivision.

In addition to the “nanoimprinting” business, Medicare's progress in its business layout in the semiconductor device industry chain has also attracted investors' attention.

According to Medicare's 2022 annual report, it has developed a complete set of processing technology for SAW filters and solved the IDT layer morphology problem. The RF chip SAW products developed have already passed some customer certification in the Q4 quarter of that year, and achieved small-batch production.

At the performance conference held today, some investors were concerned and asked, “What are the main application areas, trial production, and mass production of the company's low throughput optical filters?”

Ge Wenzhi, chairman and general manager of Medicare, did not respond positively. He only stated that the sound surface filters currently being developed by the company will be designed with filters such as low pass, band pass, and long pass according to different frequencies, and can be applied to mobile phones, WIFI, wireless communication, communication base stations, etc.

Medicare is mainly engaged in R&D, manufacturing and sales of precision optics, semiconductor optics, semiconductor micro-nano circuits, semiconductor packaging, and smart terminals.

According to the classification of application fields, Medicare mainly has four categories of products and services, including semiconductor components and precision processing services, biometric parts and precision processing services, imaging optical components, and precision processing services for AR/MR optical components.

Regarding Medicare's business performance in the first three quarters, Ge Wenzhi said that after the launch of the RF wafer project in March of this year, the company carried out R&D and sample delivery certification, achieved small-batch wafer flow in September, and climbed one after another; in terms of RF wafer packaging, small-batch production was achieved in January this year. Up to now, production capacity has reached 4K/month, and will continue to grow.

Judging from performance, in the first three quarters of this year, Medicare achieved total operating income of 241 million yuan, a year-on-year decrease of 25.62%; net profit loss of 65.1339 million yuan, profit of 8.8014 million yuan for the same period last year; net profit loss of 55.1773 million yuan, net profit loss of 55.1773 million yuan, and profit of 12.2371 million yuan for the same period last year.

Medicare said that the changes in the company's operating income in the first three quarters were mainly due to the market slump during the reporting period, some customers digested inventory, some products were upgraded, and order volume decreased; the change in net profit was mainly due to low capacity utilization during the reporting period, a year-on-year decrease in operating income, and a year-on-year increase in fixed asset depreciation, R&D expenses, etc., which led to a sharp decline in net profit.

The “Science and Technology Innovation Board Daily” reporter noticed that in addition to poor performance, Medicare's gross margin has declined markedly in the past three years. From September 30, 2021 to September 30, 2023, the company's gross margins were 50.63%, 39.16%, and 22.62%, respectively.

Medicare said that the company has been taking active measures to increase investment in R&D, develop new products, optimize product structure, obtain customer certification as soon as possible, and achieve mass production of new products.